Katie Davis

Lab Manager/Phlebotomist


  • Certified Phlebotomy Technician Program – Medical Institute of KY
  • Associates in Applied Science, Surgical Technology
    Bowling Green Technical College


  • Phlebotomist – Research Integrity, LLC
  • Owensboro Health Regional Hospital
  • Labcorp
  • Owensboro Health Regional Hospital
  • Active Day Senior Care
  • Commonwealth Health Corporation

Training & Qualifications

  • IATA: computer training; current certificate holder
  • CITI: Collaborative Institutional Training Initiative
  • Phlebotomy Technician November 3, 2015 License # R-0458
  • HIPAA Compliance & Training for Medical November 2, 2015
  • Basic Life Support CPR Issue Date 5/11/2018
  • Blood Draws

Clinical Research

  • A multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety, tolerability and pharmacokinetics or brexanolone in the treatment of adolescent female subjects with postpartum depression.  SAGE  547-PPD-304
  • A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety and pharmacokinetic of SAGE -217 in the treatment of adult female subjects with severe postpartum depression.  SAGE 217-PPD-201
  • A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of Efpeglenatide of Cardiovascular outcomes in Type 2 Diabetes Patients at high cardiovascular risk.  SANOFI EFC 14828
  • Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in Hypogonadal men (TRAVERSE) study.   ABBVIE M16-100
  • A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled, forced titration, 12-week comparison of combined angiotensin-neprilysin inhibition with sacubitril and valsartan versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction. EVALUATE CLCZ696BUS08
  • A randomized, parallel-group, placebo-controlled, double blind, multi-center trial to evaluate the efficacy and safety of the oral sGC stimulator vericiguat to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction.  VITALITY BAYER 19334